Mereo BioPharma (MREO) Accumulated Expenses (2022 - 2026)

Mereo BioPharma (MREO) has reported Accumulated Expenses for 5 consecutive years, with $2.0 million the latest figure, recorded in Q1 2026.

• Quarterly Accumulated Expenses fell 30.22% year-over-year to $2.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.0 million (down 30.22% YoY) and the FY2025 annual result came in at $2.0 million, down 50.23% from the prior year.
• Accumulated Expenses rose to $2.0 million in Q1 2026 per MREO's latest filing, from $2.0 million in the prior quarter.
• Over the last five years, Accumulated Expenses for MREO reached as high as $5.5 million in Q4 2023 and fell as low as $2.0 million in Q4 2025.
• A 5-year average of $3.7 million and a median of $3.7 million in 2024 frame the typical range for Accumulated Expenses.
• The largest YoY upside for Accumulated Expenses was 35.47% in 2025 against a maximum downside of 50.23% in 2025.
• Year by year, Accumulated Expenses stood at $5.4 million in 2022, then grew by 0.57% to $5.5 million in 2023, then slipped by 25.54% to $4.1 million in 2024, then plunged by 50.23% to $2.0 million in 2025, then rose by 0.99% to $2.0 million in 2026.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $2.0 million, $2.0 million, and $4.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.